Celltrion’s manufacturing ops figure in AstraZeneca buyout buzz

Rumors are swirling that AstraZeneca may have its sights set on the Korean biosimilars maker, and a buyout would give the British drugmaker–or any of its rivals–an established biologics plant in a strategic location, and one that's expanding, at that.